Could a pill and gel combo restore skin color in vitiligo?

NCT ID NCT07251595

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called SHR0302, given as a tablet and a gel, for people with non-segmental vitiligo. The goal is to see if it can safely and effectively bring back skin color. About 176 adults aged 18 to 75 will take part, and some will receive a placebo to compare results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR0302 (a JAK inhibitor) taken as a tablet and applied as a gel
What this could lead to: If successful, this could offer a new treatment option to help restore skin color in people with vitiligo.
What could go wrong: This is an early Phase 2 trial with only 176 participants, so results may not apply to everyone. The drug may cause side effects or not work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SEGMENTAL VITILIGO

Contacts and locations

Locations

Dermatology Hospital affiliated to Shandong First Medical University
RECRUITING

Jinan, Shandong, 250022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.